Metropolis Healthcare Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Metropolis Healthcare Limited's successfully transitioned to public market status with its listing on NSE, BSE on Apr 15, 2019. The IPO mobilized 1,36,85,095 Shares in cumulative capital, including TBD for corporate expansion.
The public offering was conducted within the price parameters of ₹877 to ₹880, with minimum investment lots of 17 shares. subscription activity between Apr 03, 2019 and Apr 05, 2019 demonstrated market reception to the company's valuation and growth narrative.
The allotment process concluded on Apr 10, 2019, finalizing share distribution to successful bidders. The listing represents a transformational event, providing the company with enhanced market visibility, regulatory compliance framework, and access to diversified investor capital.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 1980, Mumbai-based Metropolis Healthcare Limited is a chain of diagnostic companies operating 106 clinical laboratories and 1,130 collection centers across seven countries, with a presence in 18 states and 173 cities in India for disease monitoring, early detection, and diagnostic screening. The company offers 3,480 clinical laboratory tests and 524 profiles, combining various tests for specific diseases, and serves around 7.7 million patients annually, conducting approximately 16 million tests. It also provides analytical and support services for clinical research projects and follows a 'hub and spoke' model to enhance service delivery. Internationally, Metropolis has laboratory operations in Ghana, Zambia, Kenya, Sri Lanka, and Mauritius, and offers third-party services in UAE, Nepal, Nigeria, and Oman. The company has been recognized for excellence in customer service and delivery by Biotrains, for service excellence by FICCI, and as "best in health and fitness" by LH Insights in 2018.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Industry-Ready: Well-positioned to benefit from expected industry growth.
- Widespread Operations: Extensive operational network across regions.
- Comprehensive Test Menu: Offers a broad range of testing services.
- Quality & Service Focus: Emphasizes high-quality standards and customer satisfaction.
- Strong IT Infrastructure: Robust technology systems supporting operations.
NA
- Dr Sushil Kanubhai Shah
- Ameera Sushil Shah
- Metz Advisory LLP
Metropolis Healthcare Limited
Link Intime India Private Ltd